Transarterial (Chemo)embolization for Patients with Liver Metastasis of Neuroendocrine Tumors Abstract #926

Introduction: Neuroendocrine Tumors (NETs) are slowly growing tumors with an indolent course. NETs often present with liver metastasis, and most of these tumors are inoperable at the time of presentation. Transarterial (chemo)embolization [TA(C)E] is widely available to manage liver metastasis of NET.
Aim(s): To evaluate the efficacy and adverse events in patients with NET treated with TA(C)E.
Materials and methods: Forty-three patients with metastatic neuroendocrine tumors who underwent TA(C)E between December 1999 and June 2013 in National Cancer Center Hospital and National Cancer Center Hospital East were included in this retrospective study. We assessed the tumor response, disease control rate, progression-free survival, and adverse events of TA(C)E.
Conference: 11th Annual ENETS Conference 2014 (2014)
Category: Medical treatment - Others
Presenting Author: Hiroyuki Okuyama

To read results and conclusion, please login ...

Further abstracts you may be interested in

#109 Transarterial chemoebolization (TACE) of liver metastases derived from neuroendocrine tumors is an effective treatment only in patients with low or mediate hepatic tumor burden
Introduction: The onset of metastases in patients with neuroendocrine tumors of the gastrointestinal tract (GEP-NET) represents a negative predictor of survival and tumor-associated complications. Thereby, most of these patients develop liver metastases during their disease. Transarterial chemoembolization (TACE) has been shown before to be an effective and safe treatment of liver metastases. However, the optimal time point in treatment of liver metastases has not yet been determined, especially in patients with non-functional GEP-NET.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr Anja Rinke
Authors: Rinke A, König A, Müller D, König U, ...
#519 Effectiveness of Transarterial Embolization in Neuroendocrine Tumors
Introduction: Neuroendocrine tumors (NETs) with liver metastases have a poor prognosis. Somatostatin analogues and chemotherapy are used with some success. Transarterial Embolization (TAE) is increasingly used to improve symptom control and reduce tumor size.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Dr Dalvinder Mandair
#522 Effects of Transarterial Chemoembolization of Liver Metastases from Neuroendocrine Tumors on Clinical Outcome
Introduction: Trans-catheter arterial chemoembolization (TACE) is a method of treatment of non-resectable liver metastases from neuroendocrine tumors (NET) which provides control of clinical symptoms and tumor growth.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Dr Sanja Ognjanovic
#528 Trans-Arterial Embolization (TAE) is the Best Locoregional Treatment Option for Patients with Liver Metastases from Neuroendocrine Tumors
Introduction: Trans-arterial embolization (TAE) and chemoembolization (TACE) have been shown to be effective in patients (pts) with liver metastases (LM) from gastroenteropancreatic neuroendocrine tumor (GEP NET). TAE and TACE goal is to reduce blood flow to the tumor resulting in ischemia and necrosi.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Michela Del Prete
Keywords: TAE, TACE, NET
#1888 Selective Transarterial Embolization of Gastro-Entero Pancreatic (GEP) Neuroendocrine Tumors (NET) with Advanced Locoregional Disease and/or Liver Metastases
Introduction: Selective transarterial embolization(TAE) and chemoembolization(TACE),are alternative options to systemic therapies in patients with GEP-NET G1/G2 with advanced locoregional disease and/or unresectable liver metastases
Conference: 14th Annual ENETS conference 2017 (2017)
Category: PRRT-Ablative therapies- Endoscopic treatment, surgical treatment
Presenting Author: Dr Concepcion Blanco
Keywords: TACE, TAE, GEP-NET